UNAIDS. Fact sheet 2022. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed 1 Oct 2022
Kowalska JD, Skrzat-Klapaczyńska A, Bursa D, Balayan T, Begovac J, Chkhartishvili N, et al. HIV care in times of the COVID-19 crisis - where are we now in Central and Eastern Europe? Int J Infect Dis. 2020;96:311–4. https://doi.org/10.1016/j.ijid.2020.05.013.
Budak JZ, Scott JD, Dhanireddy S, Wood BR. The impact of COVID-19 on HIV care provided via telemedicine-past, present, and future. Curr HIV/AIDS Rep. 2021;18(2):98–104. https://doi.org/10.1007/s11904-021-00543-4.
Luis H, Fridayantara WD, Mahariski P, Wignall FS, Irwanto I, Gedela K. Evolving ART crisis for people living with HIV in Indonesia. Lancet HIV. 2020;7(6):e384–5. https://doi.org/10.1016/S2352-3018(20)30138-7.
GLAAD. Invisible people. A retrospective report on the impacts of COVID & HIV in the United States. https://www.glaad.org/sites/default/files/Invisible%20People%20Report%20-%20COVID%20%26%20HIV%20-%20United%20States%20-%20GLAAD%20-2022-1.pdf. Accessed 1 Oct 2022
Ambrosioni J, Blanco JL, Reyes-Urueña JM, Davies MA, Sued O, Marcos MA, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8(5):e294–305. https://doi.org/10.1016/S2352-3018(21)00070-9.
de Lazzari E, Blanco J, Rico N, Filella X, Egri N, Ruiz R, et al. Prevalence, risk factors and the impact of antiretroviral treatment in SARS-CoV-2 infection in people with HIV: a cross-sectional study. HIV Glasgow, 23–26 October 2022, Glasgow, UK / Virtual. J Int AIDS Soc. 25:e26009.https://doi.org/10.1002/jia2.26009
Fursa O, Bannister W, Neesgaard B, Podlekareva D, Kowalska J, Benfield T, et al. Prevalence, outcomes, and factors associated with testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among people living with. HIV across Europe in the multinational EuroSIDA cohort HIV Glasgow, Glasgow, UK / Virtual. J Int AIDS Soc. 2022;25:e26009. https://doi.org/10.1002/jia2.26009.
Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016-35.e19. https://doi.org/10.1016/j.cell.2020.04.035.
Huang J, Xie N, Hu X, Yan H, Ding J, Liu P, et al. Epidemiological, virological and serological features of coronavirus disease 2019 (COVID-19) cases in people living with human immunodeficiency virus in Wuhan: a population-based cohort study. Clin Infect Dis. 2021;73(7):e2086–94. https://doi.org/10.1093/cid/ciaa1186.
Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069. https://doi.org/10.1001/jamanetworkopen.2020.37069.
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. AIDS. 2020;34(12):1775–80. https://doi.org/10.1097/QAD.0000000000002643.
Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–41. https://doi.org/10.7326/M20-3689.
Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): a prospective observational study. Clin Infect Dis. 2021;73(7):e2095–106. https://doi.org/10.1093/cid/ciaa1605.
Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24–32. https://doi.org/10.1016/S2352-3018(20)30305-2.
Ceballos ME, Ross P, Lasso M, Dominguez I, Puente M, Valenzuela P, et al. Clinical characteristics and outcomes of people living with HIV hospitalized with COVID-19: a nationwide experience. Int J STD AIDS. 2021;32(5):435–43. https://doi.org/10.1177/0956462420973106.
Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022;9(7):e486–95. https://doi.org/10.1016/S2352-3018(22)00097-2.
Hoffman SA, Costales C, Sahoo MK, Palanisamy S, Yamamoto F, Huang C, et al. SARS-CoV-2 neutralization resistance mutations in patient with HIV/AIDS, California, USA. Emerg Infect Dis. 2021;27(10):2720–3. https://doi.org/10.3201/eid2710.211461.
Vizcarra P, Pérez-Elías MJ, Quereda C, Moreno A, Vivancos MJ, Dronda F, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554–64. https://doi.org/10.1016/S2352-3018(20)30164-8.
Shalev N, Scherer M, LaSota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2294–7. https://doi.org/10.1093/cid/ciaa635.
Lee MJ, Snell LB, Douthwaite ST, Fidler S, Fitzgerald N, Goodwin L, et al. Clinical outcomes of patients with and without HIV hospitalized with COVID-19 in England during the early stages of the pandemic: a matched retrospective multi-centre analysis (RECEDE-C19 study). HIV Med. 2022;23(2):121–33. https://doi.org/10.1111/hiv.13174.
Bachelard A, Sautereau A, Digumber M, Isernia V, Phung B, Lehur AC, et al. Risk factors associated with severe/critical COVID-19 in people living with HIV-1. Int J Infect Dis. 2022;122:152–4. https://doi.org/10.1016/j.ijid.2022.05.055.
Olalla-Sierra J, Martín-Escalante MD, García-Alegría J, Rubio-Rivas M, de Miguel-Campo B, Zurita-Etayo M, et al. Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain. AIDS. 2022;36(5):683–90. https://doi.org/10.1097/QAD.0000000000003056.
Favara G, Barchitta M, Maugeri A, Faro G, Agodi A. HIV infection does not affect the risk of death of COVID-19 patients: a systematic review and meta-analysis of epidemiological studies. J Glob Health. 2022;12:05036. https://doi.org/10.7189/jogh.12.05036.
• Del Amo J, Polo R, Moreno S, Jarrín I, Hernán MA. SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment. AIDS. 2022;36(2):161–8. https://doi.org/10.1097/QAD.0000000000003132. (Recent literature review which critically examined incidence and clinical outcome of COVID-19 in PLWH, showing that the risk of SARS-CoV-2 infection in such population is not hightnened and that clinical severity is not homogeneous among PLWH, increasing with age and baseline comorbidities.)
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, et al. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS. 2022;36(12):1689–96. https://doi.org/10.1097/QAD.0000000000003314.
Del Amo J, Polo R, Moreno S, Martínez E, Cabello A, Iribarren JA, et al. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. AIDS. 2022;36(15):2171–9. https://doi.org/10.1097/QAD.0000000000003372.
Ayerdi O, Puerta T, Clavo P, Vera M, Ballesteros J, Fuentes ME, et al. Preventive efficacy of tenofovir/emtricitabine against severe acute respiratory syndrome coronavirus 2 among pre-exposure prophylaxis users. Open Forum Infect Dis. 2020;7(11):ofaa455. https://doi.org/10.1093/ofid/ofaa455.
Fernandes DE, Ferreira PRA, Mastroianni KG. Pre-exposure prophylaxis during the SARS-CoV-2 pandemic: can PrEP prevent COVID-19-related symptoms? Epidemiol Infect. 2020;148:e231. https://doi.org/10.1017/S0950268820002253.
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;253:117592. https://doi.org/10.1016/j.lfs.2020.117592.
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals (Basel). 2021;14(5). https://doi.org/10.3390/ph14050454.
Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, et al. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. J Antimicrob Chemother. 2022;77(8):2265–73. https://doi.org/10.1093/jac/dkac177.
Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;49(6):1163–86. https://doi.org/10.1007/s15010-021-01666-x.
Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210–6. https://doi.org/10.1038/s41590-021-01113-x.
Spinelli MA, Peluso MJ, Lynch KL, Yun C, Glidden DV, Henrich TJ, et al. Differences in post-mRNA vaccination SARS-CoV-2 IgG concentrations and surrogate virus neutralization test response by HIV status and type of vaccine: a matched case-control observational study. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab1009.
Lv T, Cao W, Li T. HIV-related immune activation and inflammation: current understanding and strategies. J Immunol Res. 2021;2021:7316456. https://doi.org/10.1155/2021/7316456.
Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633–45. https://doi.org/10.1016/j.immuni.2013.10.001.
Kingery JR, Safford MM, Martin P, Lau JD, Rajan M, Wehmeyer GT, et al. Health status, persistent symptoms, and effort intolerance one year after acute COVID-19 infection. J Gen Intern Med. 2022;37(5):1218–25. https://doi.org/10.1007/s11606-021-07379-z.
• Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS. 2022;36(12):F7–16. https://doi.org/10.1097/QAD.0000000000003338. (This study showed that in the backdrop of similar humoral responses compared to HIV-uninfected individuals, PLWH recovering from COVID-19 display fewer SARS-CoV-2–specific CD8+ T-cells and greater exhaustion of CD4+ T-cells; furthermore, PLWH show a higher risk of developing PASC when adjusting for other factors.)
Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–8. https://doi.org/10.1016/j.chom.2020.05.008.
Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737. https://doi.org/10.1371/journal.ppat.1008737.
Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11(1):3810. https://doi.org/10.1038/s41467-020-17665-9.
留言 (0)